

REMARKS

The title has been amended to describe more accurately the claimed invention. The specification has been amended to cross-reference related applications, to make changes that more accurately reflect the invention, and to correct typographical errors.

Amendment to the specification

The paragraphs starting at page 6, line 17, at page 6, line 22, and at page 6, line 24 have been amended in accordance with changes made to the claims noted below. The paragraph starting at page 17, line 36 has been amended to recite “administration may take place,” a change that better describes the present invention and is evident from the context. The paragraph starting at page 24, line 3 has been amended to recite mesodermal “stem” cells. This amendment corrects a typographical error; mesodermal liver cells do not exist. Support for this amendment can be found, for example, at page 23, lines 21-22.

The paragraph starting at page 25, line 32, has been amended to recite cord blood “provided by” bone marrow banks, a change that more accurately describes the present invention and better describes the source of cord blood. The paragraph starting at page 28, line 22 has been amended to recite “macrophages” (page 29, line 1) and “dendritic cells” (page 29, line 2). This change corrects a typographical error that is evident from the context; support for these changes can be found, for example, page 28, lines 24-28.

The amendment to the paragraph starting at page 30, line 24 alters the text so that it does not state that the amount of plasmid is indicated in Figure 8. The paragraph at page 32,

line 12 has been amended to recite “pAxCAhVEGF” and “pAxCAhAng1,” a change that better describes the present invention and is evident from the context. The paragraphs starting at page 35, line 20, at page 35, line 33, and at page 36, line 4 have been amended to recite “rat” GAPDH primer. This change evident from the context; support for this change is found, for example, at page 35, lines 30-31. The paragraph at page 37, line 20 has been amended to recite “diameters.” This change better describes the invention; applicants note that it is convention in the art to measure a blood vessel by its diameter. The amendment to the paragraphs starting at page 38, line 23, at page 38, line 26, and at page 38, line 33 corrects English language usage and grammar. The paragraph starting at page 43, line 10 has been amended to recite “ 1×10^9 ” and hind leg “skin.” The change at page 43, line 13 (1×10^9) generates consistent formatting. The change at page 43, line 14 (hind leg skin) better describes the experimental procedure, and is evident from the context. The paragraph starting at page 44, line 21 has been amended to recite “ 1×10^9 ,” a change that generates consistent formatting. The paragraph starting at page 44, line 28 has been amended to recite “into the cardiac muscle.” This change better describes the experiment performed; support for this amendment can be found, for example, in the description of Figure 9 at page 30, lines 29-32. The paragraph starting at page 47, line 33 has been amended to recite the “SeV” vector overflow. This change is evident from the context; support for this change can be found, for example, at page 47, line 9 and page 47, lines 34-36. The amendment to the paragraphs starting at page 49, line 11 and page 49, line 14 corrects English language usage. The paragraph starting at page 50, line 3 has

been amended to recite the left iliac artery and the left femoral artery. Support for this change can be found, for example, at page 50, lines 5-6, which recites the left inguinal region, and at page 50, lines 9-10. The paragraph starting at page 50, line 15 has been amended to recite day “14” after ischemia. This correction is evident from the context, and support for this change can be found, for example, at page 50, line 16-17, which recites two weeks after ischemia. The paragraph starting at page 51, line 8 has been amended to recite rat mesenchymal stem cells. This change corrects a typographic error and is evident from the context. Support for this change can be found, for example, at page 51, line 17 and page 51, line 19. Finally, the paragraph starting at page 53, line 1 has been amended to recite “human cervical cancer cell.” This change is evident from the context; applicants note that HeLa cells, which are described at page 53, line 3, are human cervical cancer cells, as is known in the art. These changes add no new matter.

A replacement Sequence Listing updating fields 110-170 has been submitted. No new matter has been added by the present amendment.

Amendment to the claims


Claim 3 has been amended to recite a viral vector encoding angiopoietin-1. In view of the amendment to claim 3, claims 6 and 7 have also been amended. No new matter is added by this amendment.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: 18 AUGUST 2005



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045